AVRO

AVROBIO, Inc.

1.31 USD
+0.01 (+0.77%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

AVROBIO, Inc. stock is down -4.38% since 30 days ago. The next earnings date is Mar 21, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 5 February’s closed higher than January.

About AVROBIO, Inc.

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies. Its product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.